Eisai

News

Two packets and two vials of different doses of Imfinzi

ASCO26: AZ triplet makes waves in frontline liver cancer

EMERALD-3 suggests a triplet regimen based on AstraZeneca's Imfinzi and Imjudo could be practice-changing as a frontline hepatocellular carcinoma.

News

Eisai, Biogen face delay to subcutaneous Leqembi

Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.

News

MSD, Eisai report setback in first-line kidney cancer trial

The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.

News

Most patients "won't see benefit" with Alzheimer's drugs

A review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.

News

Appeal finds NICE must reconsider Alzheimer's drugs

Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.

News

Eisai joins with Pokémon for sleep awareness drive

Eisai has launched a campaign to raise awareness of sleep disorders in Japan, via a partnership with smartphone app Pokémon Sleep.

ASCO26: AZ triplet makes waves in frontline liver cancer

Eisai, Biogen face delay to subcutaneous Leqembi

MSD, Eisai report setback in first-line kidney cancer trial

Most patients "won't see benefit" with Alzheimer's drugs

Appeal finds NICE must reconsider Alzheimer's drugs

Eisai joins with Pokémon for sleep awareness drive

Biosimilars & patient access independent of geographies or s...

Discover a new era of healthcare panel engagement: Grounded ...

Eisai

Editor's Picks